---
figid: PMC7859451__fendo-11-612396-g005
figtitle: Identified signaling pathways involved in the mediation of sensitivity/resistance
  versus endocrine therapy
organisms:
- Malus domestica
- Panax ginseng
- Cucumis sativus
- Camellia sinensis
- Tripterygium wilfordii
- Ganoderma lucidum
- Momordica charantia
- Persea americana
- Centella asiatica
- Ficus carica
- Betula pendula
- Alisma plantago-aquatica subsp. orientale
- Gynostemma pentaphyllum
- Malus pumila
- Trichosanthes kirilowii
- Bupleurum chinense
- Crataegus pinnatifida
- Gleditsia sinensis
- Actaea cimicifuga
- Eclipta prostrata
- Hibiscus syriacus
- Ganoderma lingzhi
- Carissa carandas
- Alisma plantago-aquatica
- Picrasma quassioides
- Clematis ganpiniana
- Actaea racemosa
- Bolbostemma paniculatum
- Ficus microcarpa
- Vitellaria paradoxa
- Actaea yunnanensis
- Schisandra glaucescens
- Amphipterygium adstringens
- Cnidoscolus spinosus
- Davidia involucrata
- Anemone flaccida
- Lysimachia ciliata
- Betula utilis
- Mukdenia rossii
- Trichosanthes cucumerina
- Potentilla discolor
- Ficus religiosa
- Securidaca longipedunculata
- Cleome khorassanica
- Scyphiphora hydrophyllacea
- Monteverdia robusta
- Siphonodon celastrineus
- Lipschitzia divaricata
- Walsura chrysogyne
- Chuquiraga erinacea
- Lysimachia nummularia
- Rhododendron arboreum
- Gypsophila oldhamiana
- Saussurea graminea
- Androsace umbellata
- Cussonia bancoensis
- Ibervillea sonorae
- Sandoricum koetjape
- Nematostylis anthophylla
- Hemsleya pengxianensis
- Hemsleya amabilis
- Garcinia celebica
- Megacodon stylophorus
- Euphorbia sieboldiana
- Cassipourea lanceolata
- Abies veitchii
- Mus musculus
- Rattus norvegicus
- Homo sapiens
- Mouse mammary tumor virus
organisms_ner:
- Mus musculus
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC7859451
filename: fendo-11-612396-g005.jpg
figlink: pmc/articles/PMC7859451/figure/f5/
number: F5
caption: The identified signaling pathways involved in the mediation of sensitivity/resistance
  versus endocrine therapy. The signaling pathways that involve cyclin D—cyclin-dependent
  kinase 4 and 6 (CDK4/6)/6-INK4- retinoblastoma (Rb) and phosphatidylinositol-3 kinase/mechanistic
  target of rapamycin (PI3K/mTOR) play a central role in cell cycle progression, cellular
  differentiation, growth, survival and metabolism. Dysregulation of these pathways
  results in genetic/epigenetic alterations, increased proliferation and evasion of
  apoptosis, as observed in hormone receptor-positive breast cancer (HR)+, and have
  been involved in the development of endocrine therapy resistance. PI3K/mTOR pathway
  activates S6 kinase and leads to estrogen receptor (ER) signaling activation. Activation
  of ER pathway upregulates the protein expression of cyclin D, activates cyclin D—CDK4/6/6-INK4-
  Rb pathway and increases cell cycle progression (A). The resistance to PI3K/mTOR
  pathway inhibitors occurs via an aberrant activation of RAS/RAF/MEK/ERK pathway
  that produces an additional assembly of cyclin D-CDK4/6 complexes (B). In HR+ breast
  cancer the cyclin D - CDK4/6/6-INK4- Rb pathway, in particular cyclin D and CDK4,
  is overexpressed. Activation of PI3K/mTOR pathway leads to cyclin D upregulation,
  binding and activation of CDK2 (if CDK4/6 is absent) and consecutive Rb phosphorylation
  and cell cycle progression. CDK4/6 inhibitors have synergistic effects to endocrine
  therapy (C).
papertitle: 'Natural Compounds in Sex Hormone-Dependent Cancers: The Role of Triterpenes
  as Therapeutic Agents.'
reftext: Codruţa Şoica, et al. Front Endocrinol (Lausanne). 2020;11:612396.
year: '2020'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.8872948
figid_alias: PMC7859451__F5
figtype: Figure
redirect_from: /figures/PMC7859451__F5
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7859451__fendo-11-612396-g005.html
  '@type': Dataset
  description: The identified signaling pathways involved in the mediation of sensitivity/resistance
    versus endocrine therapy. The signaling pathways that involve cyclin D—cyclin-dependent
    kinase 4 and 6 (CDK4/6)/6-INK4- retinoblastoma (Rb) and phosphatidylinositol-3
    kinase/mechanistic target of rapamycin (PI3K/mTOR) play a central role in cell
    cycle progression, cellular differentiation, growth, survival and metabolism.
    Dysregulation of these pathways results in genetic/epigenetic alterations, increased
    proliferation and evasion of apoptosis, as observed in hormone receptor-positive
    breast cancer (HR)+, and have been involved in the development of endocrine therapy
    resistance. PI3K/mTOR pathway activates S6 kinase and leads to estrogen receptor
    (ER) signaling activation. Activation of ER pathway upregulates the protein expression
    of cyclin D, activates cyclin D—CDK4/6/6-INK4- Rb pathway and increases cell cycle
    progression (A). The resistance to PI3K/mTOR pathway inhibitors occurs via an
    aberrant activation of RAS/RAF/MEK/ERK pathway that produces an additional assembly
    of cyclin D-CDK4/6 complexes (B). In HR+ breast cancer the cyclin D - CDK4/6/6-INK4-
    Rb pathway, in particular cyclin D and CDK4, is overexpressed. Activation of PI3K/mTOR
    pathway leads to cyclin D upregulation, binding and activation of CDK2 (if CDK4/6
    is absent) and consecutive Rb phosphorylation and cell cycle progression. CDK4/6
    inhibitors have synergistic effects to endocrine therapy (C).
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Pten
  - Mdk
  - ti
  - tor
  - Rorc
  - Kap
  - Napsa
  - Cdkn3
  - Hspg2
  - Per1
  - Akt1
  - Pfdn4
  - Oog1
  - ci
  - PTEN
  - RICTOR
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - RORC
  - CDKN3
  - NAPSA
  - PER1
  - AKT1
  - AKT2
  - AKT3
  - FGF1
  - FGF2
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FGF10
  - FGF11
  - FGF12
  - FGF13
  - FGF14
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - C1QA
  - C1QB
  - C1QC
  - C1R
  - C1S
  - Dsor1
  - Mtk
  - Tor
  - Egfr
  - Kap3
  - per
  - Akt
  - Cen
  - cnn
  - cd
  - bnl
  - pe
  - cl
  - Cl
  - cancer
---
